Organism	Homo sapiens, human
Cell Line Description	Farage is a B lymphocyte cell line isolated in 1990 from a Caucasian adult female patient with non-Hodgkin B cell lymphoma. The cells lack both T and myeloid surface markers, express B cell surface antigens including CD19, CD20, CD22, HLA-DR, were positive for C3 receptors and EBNA and expressed BCL-2. No immunoglobulin determinants could be demonstrated on the cell surface. When treated with interleukin 4 (IL-4), Farage cells exhibit increased expression of several markers including CD23, CD54, and CD58, along with decreased levels of CD21, CD22, and CD38. This modulation of surface markers suggests a role for IL-4 in influencing B cell behavior and provides a useful model for exploring signaling pathways and regulatory mechanisms in B cells. The response to phorbol 12-myristate 13-acetate (PMA) treatment, which results in the down-regulation of CD21 and CD23, further supports its application in studying kinase-driven signaling in B-cells. Additionally, the presence of Epstein-Barr virus (EBV) in these cells allows for the study of viral interactions with host cell machinery, particularly in the context of lymphocyte oncogenesis.
Disease	Lymphoma; Non-Hodgkin's B Cell
Morphology	Lymphoblast

https://www.creative-biogene.com/support/farage-cell-line.html

Creative Biogene

Creative Biogene provides kits, reagents, and services that help researchers explore questions about gene discovery, regulation, and function. Creative Biogene holds a leadership position in the global market and is committed to improving the human condition through biotechnology.
Creative Biogene is a US-based manufacturer and provider of genomics and proteomics products and services for academic and governmental research institutes, pharmaceutical and biotechnology industry.

Our Mission

To become the premier provider of innovative technologies, products, unique tools and services for research discoveries and product development in the areas of biological and biomedical research. Emphasis will be placed on the manufacture and distribution of genomics and proteomics based biological research reagent products of the highest possible quality, which include nucleic acid, protein and antibody based research reagent products and services.